Nomura Asset Management Co. Ltd. Reduces Stake in United Therapeutics Corporation $UTHR

Nomura Asset Management Co. Ltd. trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 39.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,069 shares of the biotechnology company’s stock after selling 8,477 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $3,755,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of UTHR. IFP Advisors Inc raised its stake in shares of United Therapeutics by 103.4% during the 1st quarter. IFP Advisors Inc now owns 1,739 shares of the biotechnology company’s stock worth $536,000 after buying an additional 884 shares during the last quarter. Allianz Asset Management GmbH grew its stake in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after acquiring an additional 33,254 shares during the last quarter. AE Wealth Management LLC purchased a new position in United Therapeutics during the 1st quarter valued at about $248,000. Avantax Advisory Services Inc. raised its position in United Therapeutics by 226.5% during the first quarter. Avantax Advisory Services Inc. now owns 1,933 shares of the biotechnology company’s stock worth $596,000 after acquiring an additional 1,341 shares during the last quarter. Finally, Assetmark Inc. raised its position in United Therapeutics by 20.8% during the first quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company’s stock worth $159,823,000 after acquiring an additional 89,290 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.0%

Shares of NASDAQ:UTHR opened at $474.82 on Friday. The company has a market cap of $20.44 billion, a P/E ratio of 17.99, a P/E/G ratio of 4.96 and a beta of 0.77. The business has a fifty day simple moving average of $439.78 and a 200-day simple moving average of $355.47. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $485.32.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business posted $6.39 earnings per share. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of several research reports. UBS Group increased their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Cantor Fitzgerald upped their target price on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Bank of America raised their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company boosted their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $505.00.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $400.56, for a total value of $9,012,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 519,935 shares of company stock worth $224,879,377. Corporate insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.